Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity

Case reports

M. Saulino, A. W. Burton, D. A. Danyo, S. Frost, J. Glanzer, D. R. Solanki

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Seven cases of combination of intrathecal (IT) ziconotide and baclofen therapy in patients with refractory neuropathic pain and spasticity were reviewed. Five of the seven adult patients were receiving IT baclofen treatment when ziconotide was initiated. All five patients had experienced at least one previous failed IT treatment regimen. Pain intensity scores improved by a mean of 50.3% with the use of ziconotide-baclofen therapy. Mean time to onset of pain relief was 15 weeks, at a mean ziconotide dose of 3-7 μg/day. Within this group of patients, adverse events were observed in one patient, but they were not considered to be ziconotide related and subsequently resolved. The remaining two patients were receiving ziconotide treatment when baclofen was initiated. Pain intensity scores improved by 75% and 30%, respectively. Pain relief was evident at two weeks and one week, with corresponding ziconotide doses of 2.4 (ig/day and 14.4 |ig/day, respectively. One patient in this group reported adverse events, but all resolved during continued treatment with the study drugs. Treatment regimens varied between patients in these case series; each regimen used a different titration strategy and different concentrations of ziconotide and baclofen. Combination IT ziconotide and baclofen therapy may be a treatment option for patients with neuropathic pain and spasticity. Future studies are warranted to determine the optimal dosing and titration schedules for ziconotide-baclofen usage.

Original languageEnglish (US)
Pages (from-to)61-67
Number of pages7
JournalEuropean Journal of Physical and Rehabilitation Medicine
Volume45
Issue number1
StatePublished - Mar 2009

Fingerprint

Baclofen
Neuralgia
Pain
Therapeutics
ziconotide
Intractable Pain
Appointments and Schedules

Keywords

  • Analgesics
  • Baclofen
  • Pain
  • Ziconotide

ASJC Scopus subject areas

  • Rehabilitation
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity : Case reports. / Saulino, M.; Burton, A. W.; Danyo, D. A.; Frost, S.; Glanzer, J.; Solanki, D. R.

In: European Journal of Physical and Rehabilitation Medicine, Vol. 45, No. 1, 03.2009, p. 61-67.

Research output: Contribution to journalArticle

Saulino, M. ; Burton, A. W. ; Danyo, D. A. ; Frost, S. ; Glanzer, J. ; Solanki, D. R. / Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity : Case reports. In: European Journal of Physical and Rehabilitation Medicine. 2009 ; Vol. 45, No. 1. pp. 61-67.
@article{565ed258bad146868e15582798c3ba02,
title = "Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: Case reports",
abstract = "Seven cases of combination of intrathecal (IT) ziconotide and baclofen therapy in patients with refractory neuropathic pain and spasticity were reviewed. Five of the seven adult patients were receiving IT baclofen treatment when ziconotide was initiated. All five patients had experienced at least one previous failed IT treatment regimen. Pain intensity scores improved by a mean of 50.3{\%} with the use of ziconotide-baclofen therapy. Mean time to onset of pain relief was 15 weeks, at a mean ziconotide dose of 3-7 μg/day. Within this group of patients, adverse events were observed in one patient, but they were not considered to be ziconotide related and subsequently resolved. The remaining two patients were receiving ziconotide treatment when baclofen was initiated. Pain intensity scores improved by 75{\%} and 30{\%}, respectively. Pain relief was evident at two weeks and one week, with corresponding ziconotide doses of 2.4 (ig/day and 14.4 |ig/day, respectively. One patient in this group reported adverse events, but all resolved during continued treatment with the study drugs. Treatment regimens varied between patients in these case series; each regimen used a different titration strategy and different concentrations of ziconotide and baclofen. Combination IT ziconotide and baclofen therapy may be a treatment option for patients with neuropathic pain and spasticity. Future studies are warranted to determine the optimal dosing and titration schedules for ziconotide-baclofen usage.",
keywords = "Analgesics, Baclofen, Pain, Ziconotide",
author = "M. Saulino and Burton, {A. W.} and Danyo, {D. A.} and S. Frost and J. Glanzer and Solanki, {D. R.}",
year = "2009",
month = "3",
language = "English (US)",
volume = "45",
pages = "61--67",
journal = "European Journal of Physical and Rehabilitation Medicine",
issn = "1973-9087",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity

T2 - Case reports

AU - Saulino, M.

AU - Burton, A. W.

AU - Danyo, D. A.

AU - Frost, S.

AU - Glanzer, J.

AU - Solanki, D. R.

PY - 2009/3

Y1 - 2009/3

N2 - Seven cases of combination of intrathecal (IT) ziconotide and baclofen therapy in patients with refractory neuropathic pain and spasticity were reviewed. Five of the seven adult patients were receiving IT baclofen treatment when ziconotide was initiated. All five patients had experienced at least one previous failed IT treatment regimen. Pain intensity scores improved by a mean of 50.3% with the use of ziconotide-baclofen therapy. Mean time to onset of pain relief was 15 weeks, at a mean ziconotide dose of 3-7 μg/day. Within this group of patients, adverse events were observed in one patient, but they were not considered to be ziconotide related and subsequently resolved. The remaining two patients were receiving ziconotide treatment when baclofen was initiated. Pain intensity scores improved by 75% and 30%, respectively. Pain relief was evident at two weeks and one week, with corresponding ziconotide doses of 2.4 (ig/day and 14.4 |ig/day, respectively. One patient in this group reported adverse events, but all resolved during continued treatment with the study drugs. Treatment regimens varied between patients in these case series; each regimen used a different titration strategy and different concentrations of ziconotide and baclofen. Combination IT ziconotide and baclofen therapy may be a treatment option for patients with neuropathic pain and spasticity. Future studies are warranted to determine the optimal dosing and titration schedules for ziconotide-baclofen usage.

AB - Seven cases of combination of intrathecal (IT) ziconotide and baclofen therapy in patients with refractory neuropathic pain and spasticity were reviewed. Five of the seven adult patients were receiving IT baclofen treatment when ziconotide was initiated. All five patients had experienced at least one previous failed IT treatment regimen. Pain intensity scores improved by a mean of 50.3% with the use of ziconotide-baclofen therapy. Mean time to onset of pain relief was 15 weeks, at a mean ziconotide dose of 3-7 μg/day. Within this group of patients, adverse events were observed in one patient, but they were not considered to be ziconotide related and subsequently resolved. The remaining two patients were receiving ziconotide treatment when baclofen was initiated. Pain intensity scores improved by 75% and 30%, respectively. Pain relief was evident at two weeks and one week, with corresponding ziconotide doses of 2.4 (ig/day and 14.4 |ig/day, respectively. One patient in this group reported adverse events, but all resolved during continued treatment with the study drugs. Treatment regimens varied between patients in these case series; each regimen used a different titration strategy and different concentrations of ziconotide and baclofen. Combination IT ziconotide and baclofen therapy may be a treatment option for patients with neuropathic pain and spasticity. Future studies are warranted to determine the optimal dosing and titration schedules for ziconotide-baclofen usage.

KW - Analgesics

KW - Baclofen

KW - Pain

KW - Ziconotide

UR - http://www.scopus.com/inward/record.url?scp=67650459927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650459927&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 61

EP - 67

JO - European Journal of Physical and Rehabilitation Medicine

JF - European Journal of Physical and Rehabilitation Medicine

SN - 1973-9087

IS - 1

ER -